Shares of Profusa, Inc. (NASDAQ:PFSA – Free Report) are set to reverse split on Monday, August 17th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, August 16th.
Profusa Trading Down 1.5%
Shares of NASDAQ PFSA traded down $0.01 during mid-day trading on Thursday, reaching $0.95. The company had a trading volume of 197,899 shares, compared to its average volume of 224,255. The firm has a 50 day simple moving average of $2.85 and a two-hundred day simple moving average of $25.06. The stock has a market cap of $180,614.00, a P/E ratio of -0.00 and a beta of 0.52. Profusa has a 52-week low of $0.81 and a 52-week high of $1,297.50.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. Wall Street Zen raised Profusa from a “strong sell” rating to a “sell” rating in a report on Saturday, April 18th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.
Profusa Company Profile
Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.
The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.
Recommended Stories
- Five stocks we like better than Profusa
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
